Based in the Bay Area, Attovia Therapeutics is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. Dr. Hubert Chen, accomplished drug developer…
Month: March 2024
Allakos, a clinical stage biotechnology company focused on developing novel therapeutics for allergy, inflammatory and proliferative diseases, named Dr. Lee as Chief Medical Officer. Dr. Lee has over 20 years of clinical research and development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused…
Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, named Pamela Wapnick, MBA, as Chief Financial Officer. Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles. Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech…
Ambrx Biopharma, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system, named Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive…
Chartwell Partners proudly announces its collaboration with Neurogene Inc., a pioneering clinical-stage company dedicated to delivering groundbreaking genetic therapies for individuals and families grappling with rare neurological conditions on the recruitment of Julie Jordan, M.D., as their esteemed Chief Medical Officer. With a wealth of experience spanning over two decades in both industry and clinical…